Aktienanalyse zu IRulya Therapeutics Inc. (IRLA)IRLAIRulya Therapeutics Inc.

IRulya Therapeutics, Inc., formerly Quince Therapeutics, Inc., is a clinical-stage biopharmaceutical company. It is developing a novel disease-modifying therapeutic to address the unmet medical need associated with pulmonary disorders. Its lead asset, LAM-001, a proprietary investigational inhaled dry powder formulation of rapamycin whose differentiated characteristics may permit treatment of pulmonary conditions associated with dysfunctional mammalian target of rapamycin activity. It is evaluating the use of LAM-001 as a treatment for patients with pulmonary hypertension associated with interstitial lung disease (PH-ILD) and for patients with bronchiolitis obliterans syndrome post lung transplant (BOS). It also completed a Phase 2a trial, which enrolled patients with pulmonary arterial hypertension as well as patients with PH-ILD and sarcoidosis associated pulmonary hypertension (SAPH) where it achieved clinically relevant improvement across multiple endpoints, and others.

IRulya Therapeutics Inc is not a good buy right now due to its significant financial losses and weak performance indicators. The stock is currently priced at 31.09, but it has a forward P/E of 0 and a negative EPS estimate of -0.8300 for the upcoming earnings report. Additionally, the company has reported a net income loss of -39,458,000 for Q4 2025, indicating ongoing financial struggles. The main risk is its declining current ratio, which has fallen to 0.53, suggesting potential liquidity issues.